CD274 and cancer: Since 2014, six different inhibitors of PD-1 and PD-L1 were approved for cancer immunotherapy by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) (1), revolutionizing the treatment of certain cancers.